Do angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce cardiovascular events and loss of residual renal function in dialysis patients?
In dialysis patients, ACE-Is and ARBs preserve residual renal function without increasing side effects, and ARBs may specifically reduce cardiovascular events including heart failure.
This study demonstrates that ACE-Is/ARBs therapy decreases the loss of residual renal function, mainly for patients with peritoneal dialysis. Overall, ACE-Is and ARBs do not reduce cardiovascular events in dialysis patients, however, treatment with ARB seems to reduce cardiovascular events including heart failure. ACE-Is and ARBs do not induce an extra risk of side effects.
Liu et al. (Fri,) studied this question.